Skip to main content
KOREA PHARMA Co., Ltd. logo

KOREA PHARMA Co., Ltd. — Investor Relations & Filings

Ticker · 032300 ISIN · KR7032300006 KO Manufacturing
Open in API
Filings indexed 175 across all filing types
Latest filing 2025-05-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 032300

About KOREA PHARMA Co., Ltd.

https://www.koreapharma.co.kr/eng/main/…

KOREA PHARMA Co., Ltd. is a pharmaceutical company established in 1974 that specializes in the development and production of prescription-based medicines. The company has a particular focus on drugs for the Central Nervous System (CNS). Its product portfolio covers a wide range of therapeutic areas, including hepatic, gastrointestinal, antimicrobial, and antihistamine drugs. The company also offers treatments such as amino acids, antibiotics, antidotes, and antiepileptics, aiming to improve and maintain public health through its specialized pharmaceutical products.

Recent filings

Filing Released Lang Actions
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Korea Pharma, covering the period from January 1, 2025, to March 31, 2025. It contains detailed financial data, business operations, and management analysis, which fits the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and purpose of holding (management influence) for the company 'Korea Pharma'. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-05-14 Korean
합병등종료보고서(자산양수도)
M&A Activity Classification · 100% confidence The document is a 'Report on the Completion of Asset Acquisition' (합병등종료보고서) filed with the Financial Supervisory Service (FSS) in South Korea. It details the finalization of a real estate acquisition (land and building) by Korea Pharma, confirming the payment of the balance and the registration of ownership transfer. While the title mentions 'merger' (합병), the content specifically describes a 'Type Asset Acquisition' (자산양수도). This falls under corporate M&A-related activity and capital structure changes, which is best categorized as M&A Activity (TAR) within the provided schema.
2025-04-01 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (AGM) for the company '한국파마' (Korea Pharma). It details the approval of financial statements, dividend resolutions, and the election of directors and audit committee members. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2025-03-28 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details the changes in the board of directors, specifically the expiration of terms for existing outside directors and the appointment of new ones. This falls directly under the category of Board/Management Information (MANG).
2025-03-28 Korean
사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for the company 'Korea Pharma' (주식회사 한국파마) for the fiscal year ending December 31, 2024. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes (주석). This is a full financial disclosure document, not an announcement or a summary, and fits the definition of an Audit Report/Information (AR) or a comprehensive financial report. Given the structure and content, it is classified as an Audit Report. FY 2024
2025-03-20 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.